. 6. In Sprague-Dawley rats, no change in dialysate DA in the NAc was observed after a ⌬ 9 -THC dose of 0.5 mg/kg ip; a 20% increase occurred after a dose of 1.0 mg/kg ip [J. P. Chen et al., Neurosci. Lett. 129, 136 (1991)]. No change in dialysate DA in the NAc and in the caudate-putamen of Long-Evans rats was observed after ⌬ 9 -THC doses of 1.0 and 10.0 mg/kg administered by gavage [E. Castañ eda et al., Pharmacol. Biochem. Behav. 40, 587 (1991)]. In the Lewis strain of rats, however, ⌬ 9 -THC has been reported to increase dialysate DA in the NAc at doses of 0.5 and 1.0 mg/kg ip (20).
17. The observation that in the Sprague-Dawley rats naloxone reduces the effect of ⌬ 9 -THC on dialysate DA in the NAc is consistent with observations in Lewis rats (20) . 18 . S. W. Johnson and R. A. North [J. Neurosci. 12, 483 (1992) ] provided electrophysiological evidence for the existence of non-DA neurons in the VTA that tonically inhibit the DA neurons and are depressed by -opiates such as morphine. This neural system might also be the substrate of the DA-stimulating action of ⌬ 9 -THC. ⌬ 9 -THC may promote the release of endogenous opioids in the VTA, but its primary site of action could be outside the VTA, on neurons projecting to the VTA. 19 Corticotropin-releasing factor (CRF) has been implicated in the mediation of the stresslike and negative affective consequences of withdrawal from drugs of abuse, such as alcohol, cocaine, and opiates. This study sought to determine whether brain CRF systems also have a role in cannabinoid dependence. Rats were treated daily for 2 weeks with the potent synthetic cannabinoid HU-210. Withdrawal, induced by the cannabinoid antagonist SR 141716A, was accompanied by a marked elevation in extracellular CRF concentration and a distinct pattern of Fos activation in the central nucleus of the amygdala. Maximal increases in CRF corresponded to the time when behavioral signs resulting from cannabinoid withdrawal were at a maximum. These data suggest that long-term cannabinoid administration alters CRF function in the limbic system of the brain, in a manner similar to that observed with other drugs of abuse, and also induces neuroadaptive processes that may result in future vulnerability to drug dependence.
Cannabis continues to be a major drug of abuse, and as many as 9% of Cannabis users may meet criteria for substance dependence (1). Short-term exposure to Cannabis derivatives (hashish, marijuana) produces subjective emotional responses ranging from mild relaxation to panic reactions (1, 2) ; long-term use of Cannabis may result in mental lethargy and anhedonia (3) . A clear-cut abstinence syndrome is rarely reported, presumably because of the long halflife of cannabinoids, which precludes the emergence of abrupt abstinence symptoms (1), although nervousness, tension, restlessness, sleep disturbances, and anxiety have been described in humans, monkeys, and rats after termination of long-term cannabinoid administration (4) . A distinct abstinence syndrome can, however, be elicited in animals treated with cannabinoids over a long period (5) by administering a competitive cannabinoid antagonist (6) . This antagonist-precipitated withdrawal may unmask the development of underlying neuroadaptive processes that contribute to the development of cannabinoid dependence. The neurobiological substrates of cannabinoid-induced emotional responses remain to be elucidated, although they are likely to be mediated by activation of CB 1 cannabinoid receptors, which are present in the limbic system and brain nuclei that have been implicated in stress responses (7) . Psychotropic cannabinoids are potent activators of the hypothalamic-pituitary-adrenal (HPA) axis (8) , and this property may contribute to the unpleasant side effects described by users of Cannabis. A common element of withdrawal from drugs of abuse is a negative affective state that is characterized in humans by dysphoria and anxiety and in animals by a reward deficit and enhanced behavioral reactivity to stressors (9) . We report here that cannabinoid withdrawal, induced by administration of a cannabinoid CB 1 antagonist, re-sults not only in enhanced behavioral responses to stressors but also in increased release of CRF and induction of c-fos in the central nucleus of the amygdala. Our data reveal an unambiguous neurochemical response in the limbic system, attributable to long-term cannabinoid exposure, similar to that produced by other major drugs of abuse (9, 10) . This finding supports the hypothesis that cannabinoids can set in motion neuroadaptive processes in the brain that contribute to the development of substance dependence.
Among the various brain neurochemical and neuroendocrine systems that participate in the mediation of motivational aspects of drug dependence, CRF may hold a prominent position (11) . Recent evidence suggests that hypothalamic and extrahypothalamic CRF systems have a role in mediating cannabinoid-induced anxiety (12). Short-term treatment with the CB 1 cannabinoid receptor agonist (Ϫ)-⌬ 8 -tetrahydrocannabinol dimethyl heptyl (HU-210) activates the HPA axis in rats (12) . In addition to activation of the pituitary-adrenal axis by hypothalamic CRF neurons (13), brain CRF systems, particularly in the central nucleus of the amygdala, appear to mediate behavioral responses to stressors. CRF neurons and receptors in the central nucleus of the amygdala participate in the arousal-enhancing properties of psychostimulants as well as in behavioral sensitization (14) and play a key role in anxiety reactions observed during ethanol withdrawal (10, 11) . A CRF antagonist, ␣-helical CRF(9-41), can also attenuate the anxiogenic behavioral effects of HU-210. Moreover, studies with intracranial microdialysis indicate that immobilization stress as well as ethanol and cocaine withdrawal result in elevated extracellular concentrations of CRF in the central nucleus of the amygdala (10) .
We exploited the availability of a CB 1 cannabinoid receptor antagonist, SR 141716A, to evaluate the role of the central amygdaloid CRF system in the effects of short-term and long-term cannabinoid exposure as well as in cannabinoid withdrawal (15) . We used intracranial microdialysis (16, 17) to examine changes in extracellular CRF in the rat central nucleus of the amygdala in response to a single administration of either HU-210 or SR 141716A (Fig. 1D ). Release of CRF was also monitored in rats after long-term (2 weeks) exposure to HU-210 and during a behavioral withdrawal syndrome induced by injection of SR 141716A after long-term exposure to HU-210. We studied the temporal profile of the abstinence syndrome as well as anxietylike responses in different experimental groups with observational measures (18) and a defensive withdrawal test (19) previously characterized for use with cannabinoids (12) . In addition, we examined activation of the HPA stress response by measuring plasma corticosterone concentrations (20) . Finally, we examined the anatomical distribution of cannabinoid-responsive brain areas by analyzing the appearance of Fos immunoreactivity (21) , which has been an effective tool for mapping neural activity after stress (22, 23) , CRF administration (24) , and drug withdrawal (25) .
A single injection of HU-210 decreased the amount of CRF released from the central nucleus of the amygdala (Fig. 1A) . The inhibitory effects of HU-210 on CRF release were still apparent 24 hours after completion of the long-term cannabinoid treatment regimen (26) . In contrast, induction of withdrawal by SR 141716A after longterm exposure to HU-210 had the opposite effect and increased CRF efflux (Fig. 1B) . The increase in extracellular CRF concentration paralleled the progression of behavioral withdrawal symptoms over time (Fig.  1C) . The behavioral changes after administration of the cannabinoid antagonist in animals receiving long-term treatment with HU-210 were also reflected in anxiety-like responses in the defensive withdrawal test (27) and activation of the HPA axis as revealed by increased plasma corticosterone concentrations (Table 1 ). In addition, the changes in extracellular CRF concentration were accompanied by the appearance of increased Fos immunoreactivity in the central nucleus of the amygdala (Table 2 and Fig. 2 ). The distribution of Fos immunoreactivity indicated that induction of withdrawal by SR 141716A activated not only the central nucleus of the amygdala but also other stress-responsive brain sites that receive projections from this nucleus, such as the shell of the nucleus accumbens, the bed nucleus of the stria terminalis (BNST), the paraventricular nucleus of the hypothalamus (PVN), and brainstem structures involved in autonomic responses to stress, including the nucleus of the solitary tract (NTS). Cannabinoid withdrawal was associated with activation of stress-related midand hindbrain nuclei, including the ventral tegmental area, locus coeruleus, central gray, NTS, and, especially, the area postrema (Table 2 ), brain regions that are also activated during opiate withdrawal (25) and are recognized as critical for conveying stress information to the PVN, which ultimately triggers the HPA response (28).
Cannabinoid withdrawal was also associated with increased Fos immunoreactivity in extrapyramidal motor regions that are rich in CB 1 receptors (7), such as the caudate-putamen, ventral pallidum, and substantia nigra. This profile of neural activation is consistent with the dominant behavioral symptoms of cannabinoid withdrawal in rats (compulsive grooming and scratching, forepaw treading, and rubbing of the face), and it points toward involvement of the basal ganglia in the motor component of cannabinoid withdrawal. The greatest Fos immunoreactivity was found in the piriform cortex, a cortical area involved in limbic kindled seizures (29), which were observed in 2 of 10 animals.
Blockade of CB 1 receptors with SR SCIENCE ⅐ VOL. 276 ⅐ 27 JUNE 1997 ⅐ www.sciencemag.org 141716A in cannabinoid-naïve rats did not alter release of CRF in the amygdala and produced a different pattern of neuronal activation than in animals undergoing long-term HU-210 treatment. The antagonist increased Fos immunoreactivity mainly in the PVN, accumbens shell, and central gray matter, and it induced anxiety-like responses in both the defensive withdrawal test (Table 1 ) and the elevated plus-maze tests (30). However, SR 141716A did not increase plasma corticosterone concentrations in drug-naïve animals ( Table 1 ). In conjunction with earlier findings that SR 141716A can increase arousal and disrupt the sleep-waking cycle in rats (6), this observation suggests that endogenous "cannabinoid tone" may have a role in normal behavioral function without affecting HPA activity. Together, our results provide in vivo neurochemical, endocrinological, and immunocytochemical evidence that long-term exposure to cannabinoids leads to neuroadaptive changes that result in enhanced release of CRF in the central amygdala as well as activation of stress-responsive nuclei during cannabinoid withdrawal. These changes are consistent with the irritability and discomfort that have been described to occur after cessation of long-term consumption of marijuana (4) . Moreover, the neurobiological consequences of cannabinoid withdrawal, in particular the alteration in amygdaloid CRF function (9, 10) , are similar to those observed during withdrawal from ethanol, cocaine, and opiates as well as during exposure to environmental stressors. Thus, activation of the amygdaloid CRF system may have a motivational role of mediating the stress-like symptoms and negative affect that accompany withdrawal and, therefore, may be a common element in development of dependence on drugs of abuse. The demonstration that long-term exposure to a cannabinoid agonist evokes neuroadaptive processes in the limbic system that resemble those associated with other major drugs of abuse may provide a neurobiological basis for the gateway hypothesis. Cannabinoid abuse, by activating CRF mechanisms, may lead to a subtle disruption of hedonic systems in the brain that are then "primed" for further disruption by other drugs of abuse (9) . tion to cannabinoids is dosage (1) . Low doses of HU-210 abolish the behavioral response to novelty and inhibit the HPA stress response, whereas higher doses, particularly under conditions of novelty, have the opposite effect (12) , as in the test described here. Comparative analysis of the patterns of Fos expression in the withdrawal and short-term HU-210 treatment conditions demonstrated an overlap as well as a dissociation of affected brain regions ( Table 2) , implicating the involvement of different neural substrates in the anxiety-like response induced by a single high dose of cannabinoid as opposed to withdrawal from long-term cannabinoid exposure. In the central amygdala, Fos expression appeared dispersed after a single injection of HU-210, whereas after antagonist-induced withdrawal Fos-positive nuclei were densely distributed (Fig. 2) . In the BNST, immunopositive cells were found in a more medialanterior gradient during cannabinoid withdrawal, whereas Fos activation was more prominent in the lateral dorsal region after short-term cannabinoid exposure ( Table 2 ). In the hypothalamus, the PVN exhibited less Fos immunoreactivity during cannabinoid withdrawal compared with the effects of a single treatment with cannabinoid agonist. Thus, HPA activation after a single exposure to HU-210 in drugnaïve rats appears to be mediated directly by the PVN, whereas the increase in plasma corticosterone concentrations during withdrawal may involve activation of the central amygdala, transmitted to the PVN through its direct connections or by the BNST, which, in turn, may also activate the PVN. Because both the central amygdala and PVN are thought to be involved in anxiety-like behavioral responses to stress (13, 14) , these observations suggest that the balance between the contributions of both structures after acute cannabinoid treatment or antagonist-induced withdrawal may result in the particular behavioral reactivity to the novelty condition in the defensive withdrawal test. 28. P. J. Larsen and D. Mikkelsen, J. Neurosci. 15, 2609 (1995 Parsley cells recognize the fungal plant pathogen Phytophthora sojae through a plasma membrane receptor. A pathogen-derived oligopeptide elicitor binds to this receptor and thereby stimulates a multicomponent defense response through sequential activation of ion channels and an oxidative burst. An elicitor-responsive mitogen-activated protein (MAP) kinase was identified that acts downstream of the ion channels but independently or upstream of the oxidative burst. Upon receptor-mediated activation, the MAP kinase is translocated to the nucleus where it might interact with transcription factors that induce expression of defense genes.
